Continuation of Menopausal Hormone Therapy Past Age 65

Introduction to Continuation Guidelines

• The American College of Obstetricians and Gynecologists recommends that menopausal hormone therapy (MHT) can be continued past age 65 in women who started at menopause onset, but only at the lowest effective dose with annual reassessment and attempts at discontinuation, as the risk-benefit profile becomes less favorable with advancing age 1

Critical Age-Related Risk Considerations

• The North American Menopause Society indicates that initiating hormone replacement therapy after age 65 is explicitly contraindicated for chronic disease prevention due to increased morbidity and mortality 1
• Women who initiate MHT between ages 50-59 or within 10 years of menopause have the most favorable risk-benefit profile, with potential cardiovascular benefits in this younger age group (HR 0.59 for CHD in women aged 50-59) 2, 3, 4
• The Women's Health Initiative Memory Study showed that women aged 65-79 years had significantly increased dementia risk with combined estrogen-progestin (HR 2.05) and a composite outcome of dementia or mild cognitive impairment for both combined therapy (HR 1.44) and estrogen-alone (HR 1.38) 4

Mandatory Management Protocol After Age 65

• The Endocrine Society recommends that at age 65, clinicians must reassess necessity and attempt discontinuation of MHT 1
• If continuation is deemed essential for persistent severe symptoms, reduce to the lowest effective dose 1
• Conduct clinical review annually focusing on compliance, ongoing symptom burden, and emergence of new contraindications 1

Specific Risk Profile After Age 65

• For women continuing combined estrogen-progestin past age 65, the stroke risk is 33 vs 25 per 10,000 women-years (increased from baseline) 5
• Breast cancer risk increases with duration beyond 5 years and persists >10 years after discontinuation 5
• Dementia risk is significantly elevated in women 65-79 years 4

Optimal Formulation for Continuation

• The American Heart Association suggests that transdermal estradiol should be strongly preferred over oral formulations as it bypasses hepatic first-pass metabolism, reducing cardiovascular and thromboembolic risks 1
• Use the lowest effective dose: start with 14 μg/day ultra-low-dose patches if symptoms allow 1

Absolute Contraindications That May Develop

• Screen annually for new contraindications that mandate immediate discontinuation, including new diagnosis of breast cancer, cardiovascular event, venous thromboembolism, or pulmonary embolism 1, 5

Evidence-Based Decision Algorithm

• At age 65, assess current symptom burden; if vasomotor symptoms have resolved, discontinue MHT 1
• If moderate-severe symptoms persist, screen for new contraindications and reduce to the lowest effective dose 1, 5

Critical Caveats

• The primary indication for MHT is symptom management, never chronic disease prevention 1, 5
• Women continuing MHT past age 65 must understand they are accepting increased absolute risks of stroke, VTE, and potentially dementia for symptom relief 4, 5

Monitoring Requirements

• Annual clinical assessment of symptom burden and necessity of therapy 1
• Standard mammography screening per guidelines 1
• Blood pressure monitoring at each visit 5
• Assessment for new cardiovascular risk factors or symptoms 5
• Bone density assessment if considering discontinuation (to evaluate need for alternative osteoporosis therapy) 1

Menopausal Hormone Therapy Guidelines for Women Aged 60 and Above

Primary Recommendations

• The American Heart Association/American Stroke Association provides a Class 3 (harm) recommendation stating that in women ≥60 years of age or more than 10 years after natural menopause, oral estrogen-containing MHT is associated with excess stroke risk that must be weighed against clinical benefits 6, 7, 8
• The American College of Physicians explicitly contraindicates MHT initiation in women over 65 for chronic disease prevention due to increased morbidity and mortality 6, 7

Clinical Decision-Making

• For women who fall outside the parameters of being under 60 years of age or within 10 years of menopause onset, the risk-benefit profile of MHT is less favorable, with increased risks of stroke, cardiovascular events, and dementia 6
• The Endocrine Society recommends mandatory reassessment, attempted discontinuation, and if continuation is essential, reduction to the lowest effective dose with annual review for women already on MHT who reach age 65 6

Evidence Quality

• The 2024 AHA/ASA stroke prevention guidelines provide Level A evidence (highest quality from multiple RCTs and meta-analyses) for the increased stroke risk with oral estrogen-containing MHT in women ≥60 years 6, 7, 8
• Current consensus guidelines from major societies (AHA/ASA, ACOG, Endocrine Society, USPSTF) uniformly recommend against initiation after age 60 for chronic disease prevention and urge extreme caution even for symptom management 6